Dr. Nicole Lemieux Whitlatch, MD

Dr. Whitlatch practices at Enloe Health in Chico, California, part of Enloe Health.

Dr. Whitlatch's NPI, 1114190972, was assigned on April 11, 2008. Dr. Whitlatch graduated from Boston University School Of Medicine in 2002. Dr. Whitlatch's California license number on file is A108945.

Dr. Whitlatch's primary practice is Enloe Health, at 1531 Esplanade, Chico, CA 95926 in Butte County. The practice phone is (530) 332-7300.

Dr. Whitlatch's primary practice is Enloe Health in Chico, California, part of Enloe Health. Dr. Whitlatch is also affiliated with Oroville Hospital. The medical group on file is Enloe Specialty Physicians. Dmand AI also links Dr. Whitlatch to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Whitlatch practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Whitlatch's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Whitlatch is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Whitlatch's licenses on file in 3 states: California, Virginia and North Carolina.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, deep vein thrombosis (DVT), fluid and electrolyte imbalances, lung cancer and lymphoma among the conditions Dr. Whitlatch treats.

CMS data shows 1,207 Medicare services from Dr. Whitlatch across 8 procedure codes in 2024, for 433 Medicare patients. Medicare paid $98,025 for them.

CMS counts 433 Medicare patients who saw Dr. Whitlatch in 2024. The largest group is 65 to 74, with 211 patients. 75% of them have cancer, and 72% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.24, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Whitlatch's median patient age at 74, with 99% women.

In 2024, Dr. Whitlatch wrote 1,123 Medicare Part D claims for 286 patients. 89% of them were for generic drugs. CMS names the drug for 976 of them, across 15 drugs with 11 or more claims each, at $1,030,747 in total drug cost. In 2023, CMS named 850 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Whitlatch for performance year 2024, reported as part of a group. Dr. Whitlatch accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Whitlatch as offering telehealth.

Dmand AI links 5 papers to Dr. Whitlatch, published from 2008 to 2010. The most frequent topics are Anticoagulants, Heparin and Platelet Factor 4. Dr. Whitlatch's most frequent co-authors are Thomas Lee Ortel, MD, Gowthami M. Arepally, MD and Bijal D. Shah, MD.

Dmand AI links Dr. Whitlatch to 1 clinical trial. Conditions studied include Breast Neoplasms, Male and Breast Neoplasms.

CMS Open Payments shows 12 general payments to Dr. Whitlatch from 5 drug and device companies from 2017 to 2023. Food and beverage make up the largest share, 69% of the total. Pfizer Inc. paid the most, $175.

Dmand AI lists 1 award for Dr. Whitlatch, most recently CMS Stage 1 EHR in 2013.

Dr. Whitlatch graduated from Boston University School Of Medicine in 2002.

Dr. Whitlatch is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.